


In the claims:

1. **(original)** An isolated compound represented by A:



wherein

X represents independently for each occurrence O, S, or NR;

R represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, formyl, acyl, silyl, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or $-(CH_2)_m-R_{80}$;

R^1 represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxyl, aryloxy, arylalkyloxy, amino, alkylamino, arylamino, arylalkylamino, sulfhydryl, alkylthio, arylthio, arylalkylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or $-(CH_2)_m-R_{80}$;

R^2 represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, or $-(CH_2)_m-R_{80}$;

R^3 represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, or $-(CH_2)_m-R_{80}$;

R^4 is absent or present between one and four times inclusive;

R^4 , if present, represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxyl, aryloxy, arylalkyloxy, amino, alkylamino, arylamino, arylakylamino, sulfhydryl, alkylthio, arylthio, arylakylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or $-(CH_2)_m-R_{80}$;


R_{80} represents independently for each occurrence an aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl moiety;

m is independently for each occurrence an integer in the range 0 to 8 inclusive; and

the compound is a single enantiomer; or

a pharmaceutically acceptable salt or prodrug thereof.

2. **(original)** An isolated compound represented by **B**:



wherein

X represents independently for each occurrence O, S, or NR;

R represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, formyl, acyl, silyl, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or $-(CH_2)_m-R_{80}$;

R^1 represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxyl, aryloxy, arylalkyloxy, amino,

alkylamino, arylamino, arylakylamino, sulfhydryl, alkylthio, arylthio, arylakylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or $-(CH_2)_m-R_{80}$;

R^2 represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, or $-(CH_2)_m-R_{80}$;

R^3 represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, or $-(CH_2)_m-R_{80}$;

R^4 is absent or present between one and four times inclusive;

R^4 , if present, represents independently for each occurrence H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, arylalkyl, cyano, halogen, hydroxyl, alkoxyl, aryloxy, arylalkyloxy, amino, alkylamino, arylamino, arylakylamino, sulfhydryl, alkylthio, arylthio, arylakylthio, nitro, azido, alkylseleno, formyl, acyl, carboxyl, silyl, silyloxy, (alkyloxy)carbonyl, (aryloxy)carbonyl, (arylalkyloxy)carbonyl, (alkylamino)carbonyl, (arylamino)carbonyl, (arylalkylamino)carbonyl, alkylsulfonyl, arylsulfonyl, or $-(CH_2)_m-R_{80}$;

R_{80} represents independently for each occurrence an aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl moiety;

m is independently for each occurrence an integer in the range 0 to 8 inclusive; and
the compound is a single enantiomer; or

a pharmaceutically acceptable salt or prodrug thereof.

3. **(original)** The compound of claim 1 or 2, wherein X represents O.
4. **(original)** The compound of claim 1 or 2, wherein R represents H.
5. **(original)** The compound of claim 1 or 2, wherein R^1 represents H.
6. **(original)** The compound of claim 1 or 2, wherein R^2 represents H.
7. **(original)** The compound of claim 1 or 2, wherein R^3 represents alkyl.
8. **(original)** The compound of claim 1 or 2, wherein R^4 is absent.

9. **(original)** The compound of claim 1 or 2, wherein X represents O; and R represents H.
10. **(original)** The compound of claim 1 or 2, wherein X represents O; R represents H; and R¹ represents H.
11. **(original)** The compound of claim 1 or 2, wherein X represents O; R represents H; R¹ represents H; and R² represents H.
12. **(original)** The compound of claim 1 or 2, wherein X represents O; R represents H; R¹ represents H; R² represents H; and R³ represents alkyl.
13. **(original)** The compound of claim 1 or 2, wherein X represents O; R represents H; R¹ represents H; R² represents H; R³ represents alkyl; and R⁴ is absent.
14. **(original)** The compound of claim 1 or 2, wherein X represents O; R represents H; R¹ represents H; R² represents H; R³ represents ethyl; and R⁴ is absent.
15. **(original)** A formulation, comprising a compound of claim 1 or 2; and a pharmaceutically acceptable excipient.
16. **(previously presented)** A formulation, comprising a compound of claim 1 or 2; and a compound selected from the group consisting of analgesics, anti-inflammatory drugs, antipyretics, antidepressants, antiepileptics, antihistamines, antimigraine drugs, antimuscarinics, anxiolytics, sedatives, hypnotics, antipsychotics, bronchodilators, anti asthma drugs, cardiovascular drugs, corticosteroids, dopaminergics, electrolytes, gastro-intestinal drugs, muscle relaxants, nutritional agents, vitamins, parasympathomimetics, stimulants, antinarcotic, and anorectics.
17. **(original)** A formulation, comprising a compound of claim 1 or 2; and a compound selected from the group consisting of aceclofenac, acetaminophen, adomoxetine, almotriptan, alprazolam, amantadine, amcinonide, aminocyclopropane, amitriptyline, amolodipine, amoxapine, amphetamine, aripiprazole, aspirin, atomoxetine, azasetron, azatadine, beclomethasone, benactyzine, benoxaprofen, bupropion, buspirone, bicipradine, bromocriptine, budesonide, buprenorphine, bupropion, buspirone, butorphanol, butriptyline, caffeine, carbamazepine, carbidopa, carisoprodol, celecoxib, chlordiazepoxide, chlorpromazine, choline salicylate, citalopram, clomipramine, clonazepam, clonidine, clonitazene, clorazepate, clotiazepam, clobazam, clozapine,

codeine, corticosterone, cortisone, cyclobenzaprine, cyproheptadine, demexiptiline, desipramine, desomorphine, dexamethasone, dextranabinol, dextroamphetamine sulfate, dextromoramide, dextropropoxyphene, dezocine, diazepam, dibenzepin, diclofenac sodium, diflunisal, dihydrocodeine, dihydroergotamine, dihydromorphine, dimetacrine, divalproxex, dizatriptan, dolasetron, donepezil, dothiepin, doxepin, duloxetine, ergotamine, escitalopram, estazolam, ethosuximide, etodolac, femoxetine, fenamates, fenoprofen, fentanyl, fludiazepam, fluoxetine, fluphenazine, flurazepam, flurbiprofen, flutazolam, fluvoxamine, frovatriptan, gabapentin, galantamine, gepirone, ginko bilboa, granisetron, haloperidol, huperzine A, hydrocodone, hydrocortisone, hydromorphone, hydroxyzine, ibuprofen, imipramine, indiplon, indomethacin, indoprofen, iprindole, ipsapirone, ketaserin, ketoprofen, ketorolac, lesopitron, levodopa, lipase, lofepramine, lorazepam, loxapine, maprotiline, mazindol, mefenamic acid, melatonin, melitracen, memantine, meperidine, meprobamate, mesalamine, metapramine, metaxalone, methadone, methadone, methamphetamine, methocarbamol, methyl dopa, methylphenidate, methylsalicylate, methysergid(e), metoclopramide, mianserin, mifepristone, milnacipran, minaprine, mirtazapine, moclobemide, modafinil, molindone, morphine, morphine hydrochloride, nabumetone, nadolol, naproxen, naratriptan, nefazodone, neurontin, nomifensine, nortriptyline, olanzapine, olsalazine, ondansetron, opipramol, orphenadrine, oxaflozane, oxaprazin, oxazepam, oxitriptan, oxycodone, oxymorphone, pancrelipase, parecoxib, paroxetine, pemoline, pentazocine, pepsin, perphenazine, phenacetin, phendimetrazine, phenmetrazine, phenylbutazone, phenytoin, phosphatidylserine, pimozone, pirlindole, piroxicam, pizotifen, pizotiline, pramipexole, prednisolone, prednisone, pregabalin, propranolol, propizepine, propoxyphene, protriptyline, quazepam, quinupramine, reboxetine, reserpine, risperidone, ritanserin, rivastigmine, rizatriptan, rofecoxib, ropinirole, rotigotine, salsalate, sertraline, sibutramine, sildenafil, sulfasalazine, sulindac, sumatriptan, tacrine, temazepam, tetrabenazine, thiazides, thioridazine, thiothixene, tiapride, tiasipirone, tizanidine, tofenacin, tolmetin, toloxatone, topiramate, tramadol, trazodone, triazolam, trifluoperazine, trimethobenzamide, trimipramine, tropisetron, valdecoxib, valproic acid, venlafaxine, viloxazine, vitamin E, zimeldine, ziprasidone, zolmitriptan, zolpidem, and zopiclone.

18. **(original)** A method of treating a mammal suffering from depression, comprising the step of:
administering to said mammal a therapeutically effective amount of a compound of claim 1 or 2.
19. **(original)** A method of treating a mammal suffering from fibromyalgia syndrome, comprising the step of:
administering to said mammal a therapeutically effective amount of a compound of claim 1 or 2.
20. **(original)** A method of treating a mammal suffering from mental disorders including Functional Somatic Disorders, for example, depression, fibromyalgia syndrome, chronic fatigue syndrome, pain, attention deficit/hyperactivity disorder, and visceral pain syndromes (VPS), such as irritable bowel syndrome (IBS), noncardiac chest pain (NCCP), functional dyspepsia, interstitial cystitis, essential vulvodynia, urethral syndrome, orchialgia, and affective disorders, including depressive disorders (major depressive disorder, dysthymia, atypical depression) and anxiety disorders (generalized anxiety disorder, phobias, obsessive compulsive disorder, panic disorder, post-traumatic stress disorder), premenstrual dysphoric disorder, temporomandibular disorder, atypical face pain, migraine headache, and tension headache, comprising the step of:
administering to said mammal a therapeutically effective amount of a compound of claim 1 or 2.
21. **(original)** The method of claim 18, 19, or 20, wherein said mammal is a primate, equine, canine or feline.
22. **(original)** The method of claim 18, 19, or 20, wherein said mammal is a human.
23. **(original)** The method of claim 18, 19, or 20, wherein said compound is administered orally.
24. **(original)** The method of claim 18, 19, or 20, wherein said compound is administered intravenously.

25. **(original)** The method of claim 18, 19, or 20, wherein said compound is administered sublingually.
26. **(original)** The method of claim 18, 19, or 20, wherein said compound is administered ocularly.
27. **(original)** The method of claim 18, 19, or 20, wherein said compound is administered transdermally.
28. **(original)** The method of claim 18, 19, or 20, wherein said compound is administered rectally.
29. **(original)** The method of claim 18, 19, or 20, wherein said compound is administered vaginally.
30. **(original)** The method of claim 18, 19, or 20, wherein said compound is administered topically.
31. **(original)** The method of claim 18, 19, or 20, wherein said compound is administered intramuscularly.
32. **(original)** The method of claim 18, 19, or 20, wherein said compound is administered subcutaneously.
33. **(original)** The method of claim 18, 19, or 20, wherein said compound is administered buccally.
34. **(original)** The method of claim 18, 19, or 20, wherein said compound is administered nasally.
35. **(original)** A composition comprising a selective serotonin reuptake inhibitor and a compound of claim 1 or 2.
36. **(original)** A composition comprising a selective norepinephrine reuptake inhibitor and a compound of claim 1 or 2.
37. **(original)** A composition comprising a selective serotonin reuptake inhibitor, a selective norepinephrine reuptake inhibitor, and a compound of claim 1 or 2.

38. **(original)** The composition of claims 36 or 37, wherein said selective norepinephrine reuptake inhibitor is milnacipran.
39. **(original)** The composition of any one of claims 35-37, wherein said compound of claim 1 or 2 is CS1713.
40. **(original)** The composition of any one of claims 35-37, wherein said compound of claim 1 or 2 is CS1714.
41. **(original)** The composition of any one of claims 35-40, wherein said composition further comprises CS1814.
42. **(original)** A composition comprising a selective serotonin reuptake inhibitor and CS1814.
43. **(original)** A composition comprising a selective norepinephrine reuptake inhibitor and CS1814.
44. **(original)** A composition comprising a selective serotonin reuptake inhibitor, a selective norepinephrine reuptake inhibitor, and CS1814.